May 7, 2014

Press Release related to the results of Phase II clinical study on HP-3060 in Japan (a transdermal system for the treatment of allergic rhinitis)

Hisamitsu Pharmaceutical Co., Inc. (Head office: Tosu city, Saga Prefecture, Japan: President and CEO: Hirotaka Nakatomi, hereinafter referred to as “Hisamitsu”) hereby announces the results of the Phase II clinical study on a transdermal system for the treatment of allergic rhinitis (development code: HP-3060, hereinafter referred to as “the product”).

The placebo-controlled study was conducted on the pharmacokinetics, efficacy, and safety of the product in adults with allergic rhinitis. As a result, in addition to maintaining stable blood drug concentration, a statistically significant difference was confirmed for improvement in the primary efficacy endpoint compared with the placebo group. For safety, no serious adverse reactions were observed.

Based on the above results, in addition to verifying the efficacy in a Phase III clinical study, Hisamitsu will confirm the stability and efficacy in long-term administration.

The product is a systemic transdermal tape formulation developed by utilizing Hisamitsu’s TDDS (Transdermal Drug Delivery System) technology. Hisamitsu expects it to be a new option for the treatment of allergic rhinitis by realizing its long-lasting effect by means of maintaining a stable blood drug concentration.

Hisamitsu aims to initiate a Phase III clinical study during FY 2014.